Disease Markers / 2019 / Article / Tab 4

Research Article

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma

Table 4

Association of serum MMP9 with time to progression (TTP) and overall survival (OS).

HR (95% CI)HR (95% CI) adja adjaHR (95% CI)HR (95% CI) adjb adjb

Before treatment (ng/ml)1.020 (0.981-1.061)c0.3091.020 (0.981-1.061)c0.4641.033 (0.985-1.084)c0.1801.027 (0.977-1.080)c0.293
After chemotherapy (ng/ml)1.025 (0.965-1.089)c0.4201.011 (0.948-1.077)c0.7481.027 (0.951-1.109)c0.4941.007 (0.929-1.092)c0.868
Change after chemotherapy (ng/ml)0.985 (0.942-1.029)c0.4880.981 (0.936-1.028)c0.4170.973 (0.923-1.025)c0.3000.966 (0.916-1.020)c0.209
Change after chemotherapy—increase vs. decrease0.689 (0.393-1.207)0.1930.681 (0.384-1.208)0.1890. 256 (0.306-1.276)0.1970.586 (0.286-1.198)0.143
At disease progression (ng/ml)0.997 (0.929-1.069)c0.9290.975 (0.900-1.056)c0.532

aAdjusted for C-reactive protein and histological type. bAdjusted for C-reactive protein. cHazard ratios (HRs) calculated for increase of MMP9 levels for 100 ng/ml.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.